Treating Patients With Stage IV Lung Adenocarcinoma Without Actionable Oncogenic Drivers

Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Adding retifanlimab to carboplatin and paclitaxel improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

Zanidatamab combined with chemotherapy demonstrated promising antitumor activity and safety in the first-line treatment of HER2-positive mCRC, with a high response rate and manageable adverse effects.